A British pharmaceutical company AstraZeneca said today that preliminary data from a trial showed that the AZ vaccine, as an anti-epidemic booster, produced a large antibody response to Omicron and mutant viruses such as Beta, Delta, Alpha and Gamma.

(We Chinese in America Media Editor Tang Zhao, January 13, 2022) AstraZeneca said that regardless of previous vaccination with the AZ vaccine (Vaxzevria) or the messenger RNA (mRNA) vaccine, an increased immune response was seen after the third dose of the AZ vaccine. AstraZeneca said they will send the data to national drug regulators against Omicron

AstraZeneca's vaccine was co-developed with Oxford University researchers, and laboratory studies last month found that three doses of the AZ vaccine were effective against the Omicron mutated virus.

Andrew Pollard, director of the Oxford Vaccine Group, said in a statement: "These important studies show that, regardless of whether the two previous doses of the vaccine were AZ or mRNA or even inactivated vaccine, only a third dose of AZ vaccine is required., can significantly enhance immunity to COVID-19.”

A large-scale trial in the United Kingdom in December last year found that after the AZ vaccine or the Pfizer/BNT (Pfizer-BioNTech) vaccine, the third dose of the AZ vaccine could increase antibodies; but it also concluded that with BNT and Moderna, using two mRNA vaccines as supplements, the antibody increase will be the largest.

(Source: Central News Agency)